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for covalent binding and intercalation with DNA†
Dan E. Wise,a Aimee J. Gamble,b Sham W. Arkawazi, ‡b Paul H. Walton, b
M. Carmen Galan, a Michael P. O’Hagan, a Karen G. Hogg, c
Joanne L. Marrison,c Peter J. O’Toole,c Hazel A. Sparkes, a Jason M. Lynam *b
and Paul G. Pringle *a
We report cytotoxic ruthenium(II) complexes of the general formula [RuCl(cis-tach)(diphosphine)]+ (cis-
tach = cis–cis-1,3,5-triaminocyclohexane) that have been characterised by 1H, 13C and 31P{1H} NMR spec-
troscopy, mass spectrometry, X-ray crystallography and elemental analysis. The kinetics of aquation and
stability of the active species have been studied, showing that the chlorido ligand is substituted by water
at 298 K with first order rate constants of 10−2–10−3 s−1, ideal for potential clinical use as anti-tumour
agents. Strong interactions with biologically relevant duplex and quadruplex DNA models correlate with
the activity observed with A549, A2780 and 293T cell lines, and the degree of activity was found to be
sensitive to the chelating diphosphine ligand. A label-free ptychographic cell imaging technique recorded
cell death processes over 4 days. The Ru(II) cis-tach diphosphine complexes exhibit anti-proliferative
effects, in some cases outperforming cisplatin and other cytotoxic ruthenium complexes.
Introduction
Ruthenium complexes have potential as alternatives to plati-
num-based chemotherapy in the treatment of cancers.
Compounds A–G in Fig. 1 show the structural diversity of Ru
complexes whose anti-cancer activity has been investigated.1
The ruthenium(III) complexes, NAMI-A (A) and KP1019 (B) have
undergone clinical trials.2–6 More recently, Sadler7–11 and
Dyson12–17 have reported piano-stool (η6-arene)ruthenium(II)
compounds that are cytotoxic in vitro and in vivo. Notably, the
chelate complex [RuCl(η6-biphenyl)(H2NCH2CH2NH2)]PF6 (C)
has been shown to target DNA directly, with the DNA-complex
adduct stabilised by hydrogen bonds between the diamine
ligand and the O6 of guanine.18 It has been shown that
[RuCl2(p-cymene)(PTA)] (D) is active in vivo against secondary
metastases.13 In addition, due to their tunable photophysical
properties, many Ru(II) polypyridyl complexes have been devel-
oped for use in photodynamic therapy (PDT) and photoche-
motherapy (PCT).19–22 The first example of this class of com-
plexes to have entered human clinical trials was TLD1433 (E)
which contains a terthienyl chromophore.19,23
The seminal work on the anti-cancer properties of (η6-
arene)Ru complexes has spurred the investigation of many
coordination complex analogues of organometallic piano-stool
complexes. For example, Alessio et al. replaced the arene with
[9]aneS3 to give complex F with minimal loss of biological
activity compared to its organometallic analogues.24
Furthermore, Ru-diphosphine complexes such as [(κ3-tpm)
RuCl(diphos)]PF6 (G) showed activity in vitro.
25 However,
despite the variety of facially capping ligands available which
could be used to modulate activity, this aspect of the com-
plexes has received far less attention than modification of the
other ancillary ligands on the metal.26–28 From a biological
perspective, the narrow range of face-capping ligands that have
been used limits the rate and extent of the substitution of the
halido ligands by water. This rate is known to correlate with
in vitro activity,8,29,30 and expanding its range is thus a critical
factor in maximising the clinical potential of ruthenium com-
plexes in the treatment of cancer.
†Electronic supplementary information (ESI) available: Experimental, character-
isation, X-ray crystallography and detailed assay procedures. Table S3, CCDC
1959465. For ESI and crystallographic data in CIF or other electronic format see
DOI: 10.1039/d0dt02612c
‡Current address, Department of Chemistry, University of Garmian, Kurdistan
Region, Iraq.
aSchool of Chemistry, University of Bristol, Cantock’s Close, Bristol, BS8 1TS, UK.
E-mail: paul.pringle@bristol.ac.uk
bDepartment of Chemistry, University of York, Heslington, York, YO10 5DD, UK.
E-mail: jason.lynam@york.ac.uk
cImaging and Cytometry Laboratory, Bioscience Technology Facility, Department of
Biology, University of York, UK


























































































































View Journal  | View Issue
The ligand cis-tach (cis–cis-1,3,5-triaminocyclohexane)
forms face-capping complexes with many transition metals
including ruthenium(II).31–35 The labile complex [RuCl(dmso-
S)2(cis-tach)]Cl (1) is the precursor to N,N-chelate complexes
2a–c and P,P-chelate complexes 3a–f (Scheme 1) that have been
previously reported.35 The influence of the cis-tach ligand
was evaluated by comparison of the structural data with
those for (η6-arene)Ru complexes. It has previously been
demonstrated35,36 that cis-tach is a strong σ-donor, as would
be expected due to the three nitrogen atoms coordinated to
the metal. For instance, reaction of the DMSO complex 1 with
diamines yields dicationic complexes in which one co-
ordinated DMSO is retained, whereas 1 with diphosphines
gave complexes with one chlorido ligand retained (Scheme 1).
This difference in behaviour was rationalised on the basis of
the different bonding characteristics of diamines and dipho-
sphines. The electron-richness of the Ru created by the cis-
tach, is augmented by the diamine σ-donors which leads to
strong π-back-donation to the DMSO ligand, strengthening the
Ru–S interaction. By contrast, diphosphines, which are better
π-acceptors than DMSO, favour the coordination of chloride,
which is presumed to be a π-donor. Importantly, for the use of
these complexes as anti-cancer agents, it was reasoned that the
Ru(cis-tach)(diphos) moiety may promote the rapid aquation of
the Ru–Cl bond which might then result in enhanced in vitro
activity.31,37
In addition to their potential as effective anti-cancer agents,
Ru complexes of cis-tach have other features that make them
attractive for medicinal chemistry. For instance, the cationic
Ru cis-tach complexes are readily prepared as chloride salts,
obviating the use of the toxic PF6
− anion in potential pharma-
ceuticals.38 The NH2 groups of the cis-tach ligand enhance the
water solubility of the complexes and, moreover, may
strengthen any binding to DNA through hydrogen-bonding
interactions, in a similar manner to the DNA binding with
[RuCl(η6-biphenyl)(en)]PF6 (C).
8,9 Finally, the cyclohexane ring
provides a hydrophobic face to the complex, giving steric pro-
tection to the hydrophilic metal centre.
It is in this context that we now report a detailed investi-
gation of the in vitro activity of ruthenium cis-tach complexes.
It is shown that a range of diphosphine derivatives exhibit
activity against three tumour cell lines, in some cases with
potency exceeding that of cisplatin or established anti-cancer
ruthenium complexes. The extended aromatic backbones of
the new diphosphines L1–L3 (Fig. 2) are shown to allow
detailed insight into the nature of the biological interactions
with their Ru-complexes via a range of physical inorganic and
biological measurements including UV/visible, fluorescence
and NMR spectroscopy as well as label-free cellular imaging
techniques.
Results and discussion
The ruthenium(II) precursor [RuCl(dmso-S)2(cis-tach)]Cl (1)
and the (cis-tach)Ru complexes containing N,N-chelates (2a–c)
and P,P-chelates (3a–f ) were synthesised by previously reported
methods (Scheme 1).35 Our initial biological investigations
described herein focused on these complexes. Notably, for the
purposes of this study, the P,P-chelates 3a–f are freely soluble
in water up to millimolar concentrations, well in excess of that
needed for therapy.
Synthesis of diphosphine ligands and complexes
The ligands L1–L3 were made by the routes shown in
Scheme 2. The novel terthiophene diphosphine L1 was pre-
pared by route (i) from tetrabromothiophene using Pd-cata-
lysed cross-coupling.45 It was necessary to install the diphenyl-
phosphine groups in L1 sequentially to avoid the formation of
a complex mixture of products. The quinoxaline diphosphine
ligand, L2 was prepared by route (ii) following a modified lit-
erature procedure.46 The novel extended quinoxaline dipho-
Fig. 1 Cytotoxic Ru complexes.
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sphine ligand, L3 was prepared by route (iii) from its dichloro
precursor (obtained from treatment of 1,4-dihydrodibenzo[f,h]
quinoxaline-2,3-dione with PCl3 in DMF, see ESI†).
47 The
ruthenium complexes 3g–i were prepared in an analogous way
to 3a–f (route (iv)); their formation was monitored by 31P{1H}
NMR spectroscopy.
The X-ray crystal structure of [3h]PF6 (Fig. 3) demonstrates
that the addition of the larger, planar aromatic quinoxaline
diphosphine ligand L2 does not significantly alter the geome-
try of the (cis-tach)Ru complex, as shown by the overlap with
the phenylene diphosphine analogue (3f ) illustrated in Fig. 3.
The cis-tach ligand adopts the expected κ3-coordination mode
and there are intramolecular interactions detected between the
N(4)H2 and the centroids of the phenyl rings of the PPh2
groups. In addition to the lipophilic cyclohexane ring, the
PPh2 groups provide further hydrophobicity to the complex
and have the potential to interact with biomolecules (see
below).
Inhibition of the proliferation of A549 and A2780 cells
The in vitro growth inhibition was determined by MTT assay in
two cell lines: A549 (human lung adenocarcinoma) and A2780
(human ovarian adenocarcinoma). The Ru complex of bipy
(2a) in concentrations up to 300 μM, did not inhibit the
growth of tumour cells and were therefore considered inactive.
Ruthenium mono-phosphine complexes containing an η6-
arene, have previously been shown11,15,39–42 to be active against
cancer cells. We now report clear antiproliferative activity with
the P,P-chelates 3a–f as shown in Fig. 4 and some trends can be
discerned from the data. (1) The activity generally increases
Fig. 2 Chemical structures of L1–L3 designed for this work.
Scheme 2 (i)–(iii) Synthesis of ligands L1–L3. (iv) Synthesis of Ru com-
plexes 3g–i.
Scheme 1 Synthesis of complexes 2a–c and 3a–f.35
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with increasing chelate ring size: 3a < 3b < 3c ≃ 3d; complexes
3c and 3d are over twice as active as cisplatin against the A549
cell line and are equipotent to cisplatin against the A2780 cell
line. (2) Complex 3b is over twice as active as complex 3e
against both cell lines; although both 3b and 3e are 5-mem-
bered chelates, the more active chelate 3b has a less rigid back-
bone. (3) Complex 3f is significantly more active (by factors of
ca. 10 and 7 against the two cell lines) than the ostensibly
similar complex 3e. Although both 3e and 3f are rigid, 5-mem-
bered chelates, the phenylene backbone in 3f will make the
complex more lipophilic. It was also speculated that the interca-
lating potential of the planar aromatic backbone present in 3f
may also be a contributing factor in its higher activity than 3e.
To explore this hypothesis further, the (cis-tach)Ru com-
plexes 3g–i containing diphosphines with extended aromatic
surfaces: terthiophenyl diphosphine (L1), quinoxaline dipho-
sphine (L2) and dibenzo[f,h]quinoxaline diphosphine (L3) (see
Fig. 2 and Scheme 2) were tested. It was postulated that these
novel complexes might exhibit dual-function cytotoxicity by co-
valently binding to biomolecules and by intercalation with
DNA in a similar way to the functioning of the cytotoxic Pt
complex phenanthriplatin.43,44 If this were the case, it was
reasoned that 3g–i would be expected to be more active than
the first-generation Ru cis-tach complexes 3a–f.
We assessed the antiproliferative activity of 3g–i against
A549 cells by a 72-hour MTT assay and found that the com-
plexes were comparable in activity to the most active tested P,P-
chelate complexes 3c–d with IC50 values of 1.83 ± 0.66 µM for
3g, 11.81 ± 1.23 µM for 3h, and 5.06 ± 1.01 µM for 3i. Taking
into account the experimental errors inherent in the MTT
assays, the difference between the activity of 3g and 3c–d is not
statistically significant. Encouraged by the activities of these
more lipophilic derivatives, we sought to understand their
interactions with a variety of biomolecules and study their
activity in vitro. The MTT data for complexes 3g–i (Table S2†)
demonstrated that their activity was comparable to the most
active (cis-tach)Ru complexes. However, detailed time course
studies using in situ cellular imaging revealed further details
of the behaviour of the complexes and indicated that 3g–i are
significantly more active against A549 and 293T cells when
compared to cisplatin and 3f (see below).
Two potential modes of action of the Ru complexes 3a–i
were investigated. Firstly, aquation of the Ru–Cl bond to the
labile Ru–OH2 complex followed by covalent interactions with
nucleosides; and secondly, the ability of the complexes to
interact with DNA by non-covalent interactions.
Aquation of Ru–Cl complexes
The aquation products of 3b, 3c and 3h were characterised by
31P{1H} NMR spectroscopy and ESI-MS. The 31P{1H} NMR
spectra for complexes recorded in water at pH 7.4 consisted of
two singlet resonances, with one corresponding to the starting
chlorido complex, and the other to the aquated (water or
Fig. 3 ORTEP diagram of [3h]PF6 (A) and overlap with [3f ]PF6 (B), ellip-
soids are shown at the 50% probability level and hydrogen atoms
(except for the –NH2 groups) and PF6
− are omitted for clarity. Selected
bond lengths (Å) and angles (°) for [3h]PF6: Ru1–Cl1 2.4335(6), Ru1–P1
2.2857(7), Ru1–P2 2.2654(6), Ru1–N3 2.179(2), Ru1–N4 2.130(2), Ru1–
N5 2.182(2); P2–Ru1–P1 84.43(2), N4–Ru1–Cl1 170.90(6), P1–Ru1–Cl1
90.11(2), P2–Ru1–Cl1 93.92(2).
Fig. 4 Cell viability data in A549 and A2780 cells treated with cisplatin
and 3a–f to show influence of ligand backbone on cytotoxicity.
Antiproliferative activities were determined by MTT assay and dose
response curves are given in Fig. S5 and 6.† The IC50 calculated is the
concentration of drug required for 50% growth inhibition over a 72-hour
period. The error bars represent one standard deviation from three inde-
pendent experiments.
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hydroxo) complex (Scheme 3). The assignment of each reso-
nance was made by monitoring the changes upon addition
of sodium chloride to the aqueous solution (Fig. 5). The
high-resolution electrospray ionization mass spectrometry
(HR-ESI-MS) data for 3b, 3c and 3h recorded in 75% H2O/25%
MeOH supported the formation of the aquated complexes with
the molecular ion mass and isotope patterns corresponding to
the ion [Ru–Cl + OH]+ in all cases.
Kinetics of aquation
The kinetics of aquation and anation of the ruthenium cis-tach
complexes 3b, 3f and 3h were investigated by UV/Visible spec-
troscopy and compared to [RuCl(η6-bip)(en)]+ (C in Fig. 1).29
The time-evolution difference spectra for each complex are
shown in Fig. S1.† The presence of isosbestic points in each
spectrum suggests that the aquation process involves a single-
step mechanism in the formation of the aqua derivative from
the chlorido complex. The time dependence for the absor-
bance of each complex followed first order kinetics (Table 1).
The rate of aquation of 3b at physiological temperature (310 K)
corresponds to a half-life of 33 s. Therefore, the rate of aqua-
tion is not a significant factor in the in vitro activity of the
complex as aquation occurs rapidly in comparison to cell pro-
liferation (typically 24 h).
The rate constants for the aquation of 3b (6.55 ± 0.06 × 10−3
s−1) and 3c (63.9 ± 6.0 × 10−3 s−1) at 298 K are approximately 5
and 15 times faster than the η6-biphenyl complex [RuCl(η6-bip)
(en)]+ (C) (1.28 × 10−3 s−1) respectively. This difference could
be attributed to a weakening of the Ru–Cl bond, as shown by
its lengthening in 3b (2.4431(14) Å) and 3c (2.4404(4) Å) when
compared to RAen complex C (2.405(6) Å), due to the large
trans-effect of the nitrogen donors in the cis-tach ligand.
The reaction rates for aquation and anation at different
temperatures allowed for the determination of the Arrhenius
activation energy (Ea), activation enthalpy (ΔH
‡) and activation
entropy (ΔS‡). The Ea and ΔH
‡ for the aquation reaction are
comparable to those reported for complex C (Table 2), consist-
ent with the fundamental mechanistic steps in the aquation
process being the same. Both 3b and 3c were found to be
stable for the duration of a typical 72 h MTT assay experiment.
Furthermore, over a two-week period at 37 °C, the 1H NMR
spectrum of 3b in 10% D2O/90% H2O did not change. Since
the rate of aquation of the Ru–Cl is rapid, the biological
activity is likely more dependent on the binding to bio-
molecules once this aquation step has taken place.
Determination of the pKa of the Ru–OH2
The pKa of metal aqua complexes can form the basis of struc-
ture–activity relationships, and it has been noted that Ru com-
plexes with higher pKa values have exhibited greater potency
in vitro.48 The UV/Visible spectra of 3b and 3c were recorded at
pH intervals between 2 and 12 at 298 K in order to determine
the pKa values for the coordinated water ligands. The data
Scheme 3 Representative aquation/anation for 3b and 3c.
Fig. 5 Stacked 31P{1H} NMR spectra of a 500 µM solution (pH 7.4) of 3c
with various chloride concentrations to assign the resonances corres-
ponding to the Ru chlorido (3c) and Ru aqua (3c’) complexes.
Table 1 First order rate constants and half-lives for the aquation of
(cis-tach)Ru complexesa
Complex T/K k/10−3 s−1 t1
2
/s
3b 288 2.09 ± 0.02 331 ± 3
3b 293 3.60 ± 0.08 192 ± 5
3b 298 6.55 ± 0.06 106 ± 1
3b 303 10.7 ± 0.20 65 ± 1
3b 310 21.0 ± 0.70 33 ± 1
3c 298 63.9 ± 6.0 10 ± 2
3f 298 2.23 ± 0.12 311 ± 17
3h 298 1.02 ± 0.01 679 ± 3
aMeasurements for the aquation of 3b, 3c, 3f and 3h (300 µM) in
aqueous solution buffered at pH 7.4 (10 mM sodium phosphate).
Table 2 Kinetic parameters for the aquation (3b and C) and anation
(3b’ and C’) reactionsa
Complex Ea/kJ mol
−1
ΔH‡/kJ mol−1 ΔS‡/J K−1 mol−1
3b 79.8 ± 0.7 77.3 ± 0.7 −27.6 ± 4.8
3b′ 84.9 ± 1.0 82.4 ± 1.0 24.4 ± 3.4
C b 75.6 ± 0.6 73.1 ± 0.6 −55.7 ± 2.0
C′ b 76.7 ± 1.3 74.1 ± 1.3 −13.6 ± 4.5
a Arrhenius activation energy (Ea), activation enthalpy (ΔH
‡) and acti-
vation entropy (ΔS‡) for the aquation and anation of 3b and 3b’ at pH
7.4. b Complex C is shown in Fig. 1; values taken from ref. 29.
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were fitted to the Henderson–Hasselbalch equation which gave
pKa values of 10.80 ± 0.06 and 10.42 ± 0.15 for 3b and 3c
respectively. The 1H NMR pH titrations, performed in H2O
with 1.6% CD3OD to provide an NMR lock signal, resulted in
pKa values of 10.85 ± 0.02 and 10.54 ± 0.02 for 3b and 3c
respectively and were therefore in good agreement with the
UV/Visible spectroscopy determinations (Fig. S2†).
The acid-dissociation constants for these complexes are
higher than those commonly obtained for (η6-arene)ruthe-
nium(II) complexes, including [Ru(OH2)(η
6-biphenyl)(en)]2+
(7.71 ± 0.01), [Ru(OH2)(η
6-tha)(en)]2+ (8.01 ± 0.03, tha = tetrahy-
droanthracene), and [RuCl(OH2)(η
6-C6H6)(PTA)]
2+ (9.2 ± 0.03).
The highest pKa values reported are obtained for O,O-chelates,
such as [Ru(OH2)(η
6-p-cymene)(malonate)]+ (9.23 ± 0.02) and
[Ru(OH2)(η
6-p-cymene)(acac)]+ (9.41 ± 0.01).8,10,48,49 The con-
clusion drawn from the pKa measurements of complexes 3b
and 3c is that the deprotonated forms are physiologically inac-
cessible by more than 3 pH units and aquation therefore
affords exclusively the aqua complex.
One likely step in the mechanism of the antiproliferative
effect of the Ru complexes 3a–i is through coordination of a
biomolecule to the site on Ru initially occupied by the chlorido
ligand. The Ru complexes share a structural feature with cis-
platin – a nitrogen donor trans to a chlorido ligand and have
favourable aquation kinetics. Additionally, the amine groups
of the cis-tach ligand are located cis to the chlorido ligand and
may have a role in strengthening interactions with a bound
molecule through hydrogen bonding. As a result of this
reasoning, the series of DNA binding experiments described
below were carried out.
Calculated speciation in biological environments
The kinetic analysis shows that the rate of aquation for (cis-
tach)Ru complexes is rapid at physiological temperature, reach-
ing equilibrium within minutes. It is of interest to understand
the extent to which these complexes are aquated outside and
within a cell and to predict the composition of species present
in each environment. In order to understand the physiological
significance of the aquation/anation equilibrium constants, we
have predicted the distribution of chlorido and aqua species for
the blood, cytoplasm and cell nucleus based on the reported
chloride concentrations (Table S1†).29,50
The equilibrium constant, K, for the aquation of 3b (K =
30.6 ± 1.7 × 10−3 M) is significantly greater than for 3c (K =
5.9 ± 0.1 × 10−3 M) and results in a considerable difference in
speciation (Fig. S3 and Table S1†). The two equilibrium con-
stants span those of the RAen complexes. The equilibrium
constant for the aquation of 3b may result in the formation
of the aqua species in the blood, cytoplasm, and cell nucleus,
leading to a greater possibility for deactivation reactions to
occur. For example, cisplatin is deactivated by glutathione
binding prior to reaching the nucleus51 and a similar process
could account for the 10-fold reduction in activity of 3b com-
pared to 3c.
The combination of a smaller equilibrium constant for
aquation and a lower pKa of the aqua species results in a
favourable proportion of 3c′ formed under different physiologi-
cal environments. It is predicted for 3c that a lower proportion
of aqua species would be present in the blood, but a high pro-
portion in the cell nucleus compared to RAen complexes.
Therefore, the proportion of aqua species for 3c is greater than
for many other Ru complexes that have been evaluated for
anti-cancer activity (Table S1†). This produces a good balance
between protection of the complex outside the cell and a
higher degree of activation inside the cell. As demonstrated by
the kinetic study, the rate at which the complex is aquated
once inside the cell is very rapid and is not a factor in the
intracellular speciation.
Interactions of 3b and 3c with nucleosides
It has been shown that [RuCl(η6-arene)(en)]+ forms strong
covalent adducts with DNA, with a preference for the N7 of
guanine residues.52–54 These interactions are strengthened by
hydrogen bonds between the en ligand and the O6 of an adja-
cent guanine residue. The reaction of 3b with 9-ethylguanine
(EtG) (see ESI†) resulted in a new guanine containing species in
the 1H NMR spectrum, evident from a new H8 resonance
(Δδ(H8) = –1.93 ppm, Fig. S4†). This is consistent with guanine
binding at the N7 position to give [Ru(EtG-N7)(dppe)(cis-tach)]2+.
Substitution of the chorido ligand with a guanine derivative
was demonstrated by the reaction of 3b with guanosine (Guo)
after incubation at 37 °C for 24 h in water. The solution was
diluted to 0.1 mM with 50% methanol in water and the ESI
mass spectrum recorded. An ion with mass and isotope
pattern corresponding to [M–Cl + Guo–H]+ (30%) and [M−Cl +
Guo]2+ (30%) was observed at m/z 911.1 and 456.2 respectively
along with chlorido (100%) and hydroxy (30%) species. In con-
trast to 3b, the reaction of 3c with EtG did not produce an
observable adduct in the 1H NMR spectrum after 24 h at
37 °C. Therefore, it is plausible that coordination to 3c of the
N7 of guanine may not be involved in the mechanism by
which this complex inhibits proliferation.
Binding of Ru to CT-DNA
The intercalating fluorescent dye ethidium bromide (EB) was
used in a competition assay with complexes 3b, 3f, 3g, 3h, 3i as
well as the known DNA intercalator [Ru(bpy)2(DPPZ)]
2+ (DPPZ =
dipyrido[3,2-a:2′,3′-c]phenazine) as a benchmark (see Fig. 6).55 A
solution of 50 µM CT-DNA and 5 µM EB ([CT-DNA]/[EB] = 10 : 1)
Fig. 6 Chemical structures of the DNA intercalating dye ethidium
bromide and the known intercalating complex [Ru(bpy)2(DPPZ)]
2+.
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was prepared and the EB-CT-DNA adduct was subjected to titra-
tion with Ru complexes. The quenching constants (KSV) were




where I0 and I are the emission intensity in the absence and
presence of quencher complex respectively, KSV is the Stern–
Volmer quenching constant and [Q] is the quencher concen-
tration. From these plots, the apparent binding constants (Kapp)
were calculated using: KEB[EB] = Kapp[complex], where KEB = 1 ×
107 M−1, [EB] = 5 µM, and [complex] is the concentration of Ru
complex which gave a 50% reduction of the initial emission
intensity of EB.
For titrations with complexes 3g, 3h, 3i, a gradual decrease
in emission was observed (Fig. 7 and Fig. S7†) implying that
these complexes outcompete the EB to interact with DNA. The
same titration was performed with 3b and 3f but no appreci-
able decrease in emission was observed for the dppe complex
indicating little intercalative interaction is present (Fig. S7†).
For 3f, the decrease was so small that a binding constant
could not be calculated and therefore intercalation is not con-
sidered a viable mode of action for this complex. The binding
constants (Kapp) for 3g, 3h and 3i are 3.07 ± 0.07 × 10
5 M−1,
1.16 ± 0.04 × 105 M−1 and 5.11 ± 0.25 × 105 M−1 respectively
(Table 3), indicating that increasing the aromatic surface of
the ligand backbone (3h to 3i) gave a five-fold increase in
binding affinity.
These binding constants are comparable, and in some
cases superior to, rigid dinuclear (η6-arene)Ru complexes pre-
viously reported.59 The apparent binding constant of the
known DNA intercalator [Ru(bpy)2(DPPZ)]
2+ was calculated as
1.75 ± 0.02 × 106 M−1, only one order of magnitude higher
than the (cis-tach)Ru complexes.
Interactions with plasmid DNA
Gel electrophoretic mobility shift assays (GEMSA) were used to
study the interactions of 3b and 3c with plasmid DNA. From
1H NMR spectroscopy and mass spectrometry experiments,
9-ethylguanine (EtG) coordination was observed with 3b,
whereas 3c showed no reaction with EtG after 24 h at 37 °C
(see ESI†). This result was mirrored in the gel electrophoresis
assays with pUC18 DNA (Fig. 8), where 3c did not alter the
Fig. 7 (A) Emission spectra of CT-DNA (50 µM) and EB (5 µM) compe-
tition assay with 3h (0–112.5 µM). (B) Stern–Volmer plots EB-CT-DNA vs.
the concentration of 3g, 3h and 3i.
Table 3 Binding (Kapp) and quenching (KSV) constants for the inter-




3g 6.13 ± 0.16 3.07 ± 0.07
3h 2.31 ± 0.08 1.16 ± 0.04




2+ 34.97 ± 0.43 17.48 ± 0.22
a Calculated as the average of triplicate experiments. bNo binding
detected.
Fig. 8 GEMSA of 3b (A) and 3c (B) with pUC18 plasmid DNA after 20 h
at 37 °C. Lanes: molecular marker (1); pUC18 (2 and 10); pUC18+ 3b or
3c (% bpe), 2.5 (3), 10 (4), 25 (5), 50 (6), 100 (7); pUC18+ 10% bpe cispla-
tin (8); pUC18 linearised by single cut with SmaI (9). bpe = base pair
equivalents.
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mobility of either the open coil (OC) or super-coiled (CCC)
forms of the plasmid under the conditions employed. However,
3b did alter the mobility of the OC and CCC forms of pUC18
DNA at concentrations above 25% bpe (base pair equivalents),
where a small shift was observed with increasing concentration
(lanes 5–7, Fig. 8). These results suggest that binding to the N7
of guanine is not involved in the mechanism of action for 3c. It
is evident that 3b and 3c (lanes 3–7, Fig. 8) have different reac-
tivity with plasmid DNA from cisplatin (lane 8, Fig. 8), indicat-
ing that these complexes may have different cellular targets
that result in cytotoxicity.
Binding to G-quadruplex DNA
G-quadruplexes are four-stranded DNA secondary structures
that form from guanine-rich sequences (Fig. 9). They attract
particular attention as an anticancer target, owing to the
occurrence of quadruplex-forming motifs at chromosome telo-
meres and in the promoter sequences of several oncogenes,
e.g. the c-myc gene.60–62 These structures can adopt a variety of
topologies characterised by the relative orientations (parallel/
antiparallel) of the DNA strands in the folded structure.63–65
Furthermore, the planar G-tetrads provide additional opportu-
nities for stacking and intercalative interactions with com-
plexes, since the dimensions are significantly larger than
those of a classical Watson–Crick base pair.66 These DNA
sequences can hypothetically be targeted with high-selectivity
in order to reduce or eliminate the off-target effects resulting
from indiscriminate binding to duplex DNA.60,66
This therapeutic hypothesis has led to many groups design-
ing G-quadruplex binders as potential anticancer agents67–70
and many metal complexes are known to bind G-quadruplexes
effectively through covalent and non-covalent interactions.71
For example, Liu et al. found that ruthenium polypyridyl com-
plexes containing 4idip (4-indoleimidazo[4,5-f ][1,10]phenan-
throline) ligands were able to selectively stabilise the human
telomeric G-quadruplex structure.68,69
As a result of the intercalating ability of 3g–i indicated by the
EB assays, we investigated the ability of the complexes to stabil-
ise G-quadruplex DNA and duplex DNA structures. The extent of
stabilisation was quantified by performing a fluorescence reso-
nance energy transfer (FRET) assay initially reported by De Cian
et al.72 (see ESI†). The change in DNA melting temperature
(ΔT1/2) induced by a Ru complex compared to that of the oligo-
nucleotide in the absence of complex provides an indication of
the capacity of the complex to stabilise the G-quadruplex struc-
ture. We chose to investigate three models of G-quadruplex DNA
and one of duplex DNA (see Fig. 9). The human telomeric
sequence (F21T) was studied in potassium- and sodium-con-
taining buffer owing to the known influence of the metal ion on
the polymorphism of this sequence.73,74 The G-quadruplex
sequence found in the c-myc oncogene promoter (FmycT) was
selected as a model of this anticancer target.
The results of the FRET experiments are shown in Fig. 9
and representative raw data in the ESI (Fig. S8†). Complexes
3g and 3h did not induce any appreciable stabilisation of
quadruplex DNA (ΔT1/2 < 3 °C at 1 μM complex) but 3i did
stabilise F21T (ΔT1/2 = + 7.5 ± 2.3 °C) in sodium-containing
buffer. Additionally, 3i was selective for quadruplex DNA
structures, stabilising the quadruplex sequence FmycT
(ΔT1/2 = + 6.2 ± 1.5 °C) whilst stabilisation of the duplex
sequence F10T (Fig. 9) was negligible. Meanwhile, the same
complex did not significantly stabilize F21T in K+-rich
buffer (ΔT1/2 < 3 °C), suggesting that as well as G4/duplex
selectivity, the complex can also discriminate between
different G-quadruplex topologies to some extent. As
a control, the well-known DNA intercalator complex
[Ru(bpy)2(DPPZ)]
2+ did not significantly stabilise quadruplex
DNA (ΔT1/2 = + 1.6 ± 0.4 °C for F21T) or duplex DNA (ΔT1/2 =
+ 1.2 ± 0.3 °C for F10T) as previously reported.67
The dibenzo[f,h]quinoxaline moiety in 3i provides a large
aromatic surface that may selectively stabilise G-quadruplex
DNA through preferential association with the large G-tetrads
Fig. 9 (A) Schematic representation of a DNA G-quadruplex. The folding of the oligonucleotide into a four-stranded structure creates a stacked
arrangement of G-tetrads, each formed by the square-planar assembly of four guanine (G) residues. The overall topology is determined by the rela-
tive orientation of the neighbouring strands (indicated by arrows) and stabilized by co-ordination to metal ions (M+). (B) Average ΔT1/2 for quadruplex
(F21T and FmycT) and duplex (F10T) DNA after treatment with Ru complexes (1 µM). Error bars show standard deviations from four experiments.
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over intercalation with Watson–Crick base pairs, akin to the
4idip examples previously reported. Complex 3i showed stron-
ger binding to quadruplex DNA than 3g and 3h in experiments
with quadruplex DNA as well as CT-DNA as previously shown.
This interesting discovery that Ru cis-tach complexes interact
with quadruplex DNA warrants further study.
LiveCyte cell imaging
The viability of A549 cells and 293T cells was assessed using
Livecyte (Phasefocus Ltd) label-free time-lapse microscopy.75,76
LiveCyte cell imaging does not require the cell to be labelled
with antibodies or cellular dyes; the cells are unperturbed and
the imaging process is not toxic to the cells; the cellular
changes measured are reported with confidence to be associ-
ated with the presence of the compounds. Conventional light
microscope imaging requires the cells to be labelled with a
DNA binding or cytoplasmic dye and requires higher energy
lasers, compared to the LiveCyte: both the labelling and the
imaging light source in conventional light microscopy may be
cytotoxic over prolonged time and needs to be considered
when interpreting results.
This technique enables quantification of the total cellular
dry mass as an indicator of cell death and growth. For A549
and 293T cells, the effect of treatment with cisplatin and 3i is
shown at 36 and 72-hour time-points (Fig. 10 and 11). For
Fig. 10 Livecyte time-lapse images of A549 control cells (A) and after
treatment with 6.25 µM cisplatin (B) and 6.25 µM 3i (C). (D) Dry mass
plot to show growth inhibition when treated with cisplatin, 3f, 3g, 3h, 3i
(all at 6.25 µM).
Fig. 11 Livecyte time-lapse images of 293T control cells (A) and after treat-
ment with 6.25 µM cisplatin (B) and 6.25 µM 3i (C). (D) Dry mass plot to show
growth inhibition when treated with cisplatin, 3f, 3g, 3h, 3i (all at 6.25 µM).
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0-hour time points and compounds 3f–h see Fig. S11–13.† The
MTT assay is an endpoint colourmetric readout of cell viability
and does not provide any visual characteristics of the cells
state. In this preliminary study, integrated image analysis soft-
ware (Livecyte Cell Analysis Toolbox) was used to extract real-
time changes in morphology and dry mass of each cell over
time. The summed mass of the cellular components excluding
water (known as dry mass, see Fig. S9 and 10†) was calculated
and for each treated population of cells used as a measure of
the combined growth and proliferation. For A549 cells
(Fig. 10D), the reduction in dry mass is greatest for 3g and 3i
followed by the slightly less active derivative 3h (which shows
comparable results to cisplatin), and 3f gave the smallest
decrease in dry mass of those tested. This difference in dry
mass reduction between cisplatin and 3f is notable as the MTT
assay derived IC50 values are within error of each other (IC50 =
2.7 µM). For 293T cells (Fig. 11D), this effect is more pro-
nounced with 3f causing significantly less reduction in dry
mass than cisplatin.
The other (cis-tach)Ru complexes 3g–i caused significant
cell death at a concentration of 6.25 µM as is evident from the
cell images and dry mass curves, and this greater activity is
consistent with 3g–i exhibiting cytotoxicity by multiple
mechanisms.
Conclusions
In summary, the compounds presented here are the first
reported examples of cytotoxic ruthenium(II) cis-tach com-
plexes. The complex [RuCl(dmso-S)2(cis-tach)]Cl (1) is obtained
in high yield and is a very useful precursor for the synthesis of
a range of ruthenium(II) derivatives. Complexes 3a–i which
contain chelating diphosphine ligands are highly active in vitro
against A549, A2780 and 293T cancer cell lines. In particular,
complexes with flexible aliphatic backbones (3c and 3d) or
planar aromatic backbones (3f–i) are the most cytotoxic, with
activity in the A549 cell line more than twice that of cisplatin,
and activity in the A2780 cell line equipotent to the clinical
drug. The pKa values for 3b–c are significantly higher that
most (arene)Ru complexes which, coupled with favourable
aquation kinetics, enables high levels of the active Ru–OH2
complex in the cell nucleus.
New analogues with planar aromatic backbones have been
shown to intercalate strongly with CT-DNA models, and, in the
case of 3i also selectively stabilise G-quadruplex DNA over
duplex DNA. The anti-proliferative effect has been monitored
by LiveCyte, label-free, time-lapse imaging and stark differ-
ences are observed between the phenylene derivative 3f and
the extended aromatic derivatives (3g and 3i). Overall, these
preliminary biological studies suggest that (cis-tach)Ru dipho-
sphine complexes exhibit a dual-action cytotoxic effect, target-
ing cellular DNA by intercalation, as well as by modes of action
involving covalent binding with DNA. This robust, water-
soluble molecular architecture could be further developed to
produce next generation ruthenium chemotherapeutic agents.
Further cell studies exploiting the tunability of phosphine
ligands that result in targeted metallodrugs are ongoing.
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